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A b s t r a c t
Immunohistochemical staining for cytokeratin 7
(CK7), KIT, and PAX2 expression was performed on 91
renal neoplasms, 37 conventional (clear cell) renal cell
carcinomas (CRCCs), 20 papillary RCCs (PRCCs), 11
chromophobe RCCs (ChCs), and 23 oncocytomas, with
available karyotypes. All ChCs, 19 PRCCs, 2 CRCCs,
and 1 oncocytoma were CK7+; all ChCs, 22
oncocytomas, 2 CRCCs, and no PRCCs expressed KIT;
PAX2 was positive in 31 CRCCs, 17 PRCCs, 20
oncocytomas, and 1 ChC. The predominant expression
profiles were as follows: CRCC, CK7–/KIT–/PAX2+
(26/37); PRCC, CK7+/KIT–/PAX2+ (17/20); ChC,
CK7+/KIT+/PAX2– (10/11); and oncocytoma,
CK7–/KIT+/PAX2+ (19/23). Cytogenetic analysis
showed that the sole PAX2+ ChC had a retained
chromosome 10, and all ChCs with chromosome 10 loss
were PAX2–. These results identify specific staining
patterns of the 4 major histologic subtypes of renal
neoplasms and raise the question of a relationship
between chromosome 10 loss and loss of PAX2
expression in ChC.
Chromophobe cell carcinoma (ChC), first described by
Thoenes et al1 in 1985, accounts for approximately 5% of
malignant renal neoplasms and consists of 2 variants, classical
and eosinophilic.2,3 The classical variant described by Thoenes
et al1 is characterized by large polygonal cells with transparent,
slightly reticulated cytoplasm and can be confused with conven-
tional renal cell carcinoma (CRCC), whereas the eosinophilic
variant, composed of intensely eosinophilic cells, resembles
oncocytoma.4 Although both variants stain positively with Hale
colloidal iron, the reaction is often weak, making ChC difficult
to differentiate from oncocytoma on the one hand and the more
aggressive “granular” variant of CRCC on the other.
Recently, Yamazaki et al5 and Petit et al6 demonstrated
overexpression of KIT in ChC by gene expression and immuno-
histochemical analysis, and Mathers et al7 highlighted cytoker-
atin (CK) 7 staining in these tumors. ChC is also characterized
by a karyotype showing loss of multiple chromosomes, espe-
cially chromosomes 1, 2, 6, 10, 13, 17, and 21. A subset of cases
shows a near-triploid karyotype, with approximately 60 to 90
chromosomes per cell.8-10 In the present study, we demonstrate
the value of CK7 and KIT in combination with PAX2, a nuclear
transcription factor that regulates the development of renal
epithelia, in defining an immunohistochemical expression pro-
file characteristic of ChC.
Materials and Methods
Patients and Tumor Samples
Formalin-fixed, paraffin-embedded tissue samples from
91 renal neoplasms with available karyotypes were selected
from the archives of the Department of Pathology, Columbia
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University Medical Center, New York, NY. All specimens
were obtained from surgical resections and represented 91
successive renal cortical neoplasms in which karyotyping
demonstrated clonal abnormalities. No patient had received
previous treatment. H&E-stained slides of each case were
reviewed, and each case was typed according to the World
Health Organization classification of renal neoplasms.11 The
Fuhrman histologic grade was recorded for each carcinoma.
Papillary carcinomas were subclassified as type 1 and type 2,
according to Delahunt and Eble,12 and each ChC was classi-
fied as classical, mixed, or eosinophilic.
Cases comprised the following: 37 CRCCs (clear cell; 17
grade 2, 17 grade 3, and 3 grade 4), 20 papillary-type RCCs
(PRCCs; 16 type 1 and 4 type 2; 15 grade 2 and 5 grade 3), 11
ChCs (4 eosinophilic variant, 2 classical, and 5 mixed; 3 grade
2, 7 grade 3, and 1 grade 4), and 23 oncocytomas.
Tissue microarrays were prepared, as previously
described,13 selecting 3 cores of tumor and 1 core of normal
tissue from each case.
Immunohistochemical Analysis
Five-µm sections of tissue microarrays were deparaf-
finized and rehydrated. Following microwave antigen retrieval
in citrate, pH 6, slides were stained on a DAKO Autostainer
(DAKO, Carpinteria, CA) for CK7 and KIT and a Ventana
NEXes instrument (Ventana Medical Systems, Tucson, AZ)
for PAX2. The antibodies used were CK7 (clone OV-TL
12/30, dilution 1:200; DakoCytomation, Carpinteria, CA),
KIT (clone 104D2, dilution 1:400; DakoCytomation), and
PAX2 (polyclonal, dilution 1:50; Zymed Laboratories, San
Francisco, CA). Signal was detected using the EnVision+ sys-
tem (DAKO) for CK7 and KIT and the iView DAB detection
system (Ventana Medical Systems) for PAX2.
Each core was evaluated for staining of tumor cells. A
tumor was considered positive for a stain if greater than 10%
of tumor cells showed distinct positive staining—membra-
nous or membranous and cytoplasmic for CK7 and KIT and
nuclear for PAX2.
Cytogenetics
A portion of the tumor was obtained immediately follow-
ing sectioning, and the sample was processed for cell culture.
Tumor tissue was dissociated with collagenase, and cells were
grown for short-term culture in complete RPMI medium sup-
plemented with insulin–transferrin–sodium selenate.
Cytogenetic analysis of 20 metaphase cells was performed
using standard G-banding techniques.
Statistical Analysis
Scoring of immunohistochemical staining highlighted 4
predominant expression profiles, ie, CK7+/KIT+/PAX–,
CK7+/KIT–/PAX2+, CK7–/KIT+/PAX2+, and CK7–/KIT–/
PAX2+. A Fisher exact test was used to evaluate the distribu-
tion of each phenotypic profile in the 4 tumor categories using
a 2 × 4 table.
Results
❚Table 1❚ shows the results of immunohistochemical
staining. ChCs were predominantly CK7+, KIT+, and PAX2–.
Oncocytomas, on the other hand, were negative for CK7 and
positive for PAX2, and they shared KIT staining with ChC.
CRCCs were positive only for PAX2, whereas PRCCs were
positive for CK7 and PAX2. These differences in expression
were all statistically significant ❚Table 2❚ and ❚Image 1❚.
Of the ChCs, 4 were of the eosinophilic variant and all 4
were CK7+/KIT+/PAX2–. Although the numbers are too
small for a separate analysis, this indicates potential applica-
bility of this panel as an aid to the diagnosis of this variant.
❚Table 1❚
Immunostaining Results
Histologic Type Cytokeratin 7 KIT PAX2
Clear cell (n = 37) 2 2 31
Papillary (n = 20) 19 0 17
Chromophobe (n = 11) 11 11 1
Oncocytoma (n = 23) 1 22 20
Total (n = 91) 33 35 69
❚Table 2❚
The Four Major Immunostaining Profiles of Renal Tumors*
Staining Pattern Chromophobe (n = 11) Oncocytoma (n = 23) Clear Cell (n = 37) Papillary (n = 20) P†
CK7+/KIT+/PAX2– 10 0 0 0 <.001
CK7–/KIT+/PAX2+ 0 19 3 0 <.001
CK7–/KIT–/PAX2+ 0 0 26 0 <.001
CK7+/KIT–/PAX2+ 0 0 2 17 <.001
CK, cytokeratin.
* Of 91 tumors, 77 showed one of the phenotypic profiles shown in the Table. Several cases did not fit into the predominant phenotypes: 2 cases (1 chromophobe and 1
oncocytoma) were positive for all 3 markers; 2 oncocytomas were positive for KIT and negative for CK7 and PAX2; 2 papillary carcinomas were positive for CK7 and negative
for KIT and PAX2; 8 cases (6 clear cell, 1 oncocytoma, and 1 papillary carcinoma) were negative for all 3 stains. Boldface indicates the number with “characteristic” phenotype.
† Fisher exact test for 2 × 4 table.
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Review of karyotypes of the 11 ChCs ❚Table 3❚ showed that
9 tumors had multiple chromosome losses (6 with chromo-
some 10 losses). Four tumors (cases 2, 4, 6, and 8 in Table 3)
exhibited a near-triploid karyotype with 55 to 74 chromosomes;
5 (cases 4, 5, 9, 10, and 11) were hypodiploid; 1 harbored a
chromosomal translocation, t(1;9)(q31;q22); and 1 case
showed trisomy 7 in a minority of cells, most likely reflecting
a normal variant.14 ❚Image 2❚ shows a representative
hypodiploid karyotype.
Discussion
Our results of immunohistochemical staining with CK7
and KIT are similar to those of most previously reported stud-
ies. Petit et al6 reported immunohistochemical expression of
KIT in 88% of ChCs, and Yamazaki et al5 showed that KIT
expression was up-regulated in ChC by using high-density
nucleotide arrays. Wang and Mills15 found KIT expression in
100% of eosinophilic ChCs and oncocytomas, whereas Pan et
al16 detected KIT immunoreactivity in 83% of ChCs and 71%
of oncocytomas, with neither study detecting KIT staining in
CRCC. Other investigators17 reported KIT expression in only
4 (57%) of 7 cases of ChC, but this difference could be a con-
sequence of small samples. CK7 seems to be valuable in the
differentiation of ChCs from other tumors, especially oncocy-
tomas, which are generally CK7–.7,18 However, immunostain-
ing with a single antibody in individual cases can be notori-
ously unreliable. When addressing a differential diagnostic
question in a difficult case, it is useful to have a panel of mark-
ers, some relatively specific for one condition and others for
the alternative condition(s). The demonstration of PAX2 stain-
ing in oncocytomas and not in ChCs provides such a marker.
Furthermore, the differences in KIT immunostaining provide
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❚Image 1❚ Predominant staining patterns of conventional (clear cell) renal cell carcinoma (CRCC), papillary RCC (PRCC),
chromophobe RCC (ChC), and oncocytoma (original magnification ×4).
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an additional marker to aid in the distinction between ChCs
and other tumors, especially the granular variant of CRCC.
PAX2 is a transcription factor that is essential for kidney
development, promoting the transition of mesenchyme to
epithelium. In the normal adult kidney, PAX2 protein expres-
sion is seen predominantly in the distal nephron—the distal
tubule and collecting ducts.19
Our results demonstrating frequent expression of PAX2
in CRCC and rare or absent expression in ChC are similar to
those in previous reports.18,20 Daniel et al20 demonstrated
expression of PAX2 in more than 90% of CRCCs and in 100%
of PRCCs but in only 1 of 3 oncocytomas and 1 of 4 ChCs. In
addition, in a recent study, Mazal et al18 showed expression of
PAX2 in 88% of CRCCs but in only a few PRCCs, ChCs, and
oncocytomas, despite including tumors with fewer than 10%
positive cells as positive, whereas the present study included
only tumors with greater than 10% positive cells (correspon-
ding to “++” and “+++” of Mazal et al18). Daniel et al20 used
only frozen sections and had only 3 oncocytomas. Mazal et
al18 used the same antibody and antigen retrieval as in the
present study, diluted to 1:100 (as opposed to 1:50 in the pres-
ent study). It is unclear which avidin-biotin system was used
by Mazal et al.18 We used a highly sensitive commercial strep-
tavidin peroxidase system. Subtle differences in antigen
preservation or retrieval or in signal detection can cause sig-
nificant alterations in staining rates, an inherent limitation of
immunohistochemical procedures performed on routinely
processed tissue. The Fuhrman grade, noted by Mazal et al18
to correlate with PAX2 expression only for CRCC, is an
unlikely explanation for these differences. Our samples incor-
porated a broad range of Fuhrman nuclear grades with no rela-
tionship of staining to grade.
Overall, the 4 major expression profiles “correctly” classi-
fied 72 (79%) of 91 cases. Three CRCCs exhibited the
CK7–/KIT+/PAX2+ phenotype characteristic of oncocytomas.
Two CRCCs were CK7+/KIT–/PAX2+, a profile shared with
PRCC. Although CRCC is generally easily distinguished from
oncocytoma and PRCC, it is useful to note that CRCC may
express KIT and/or CK7. Of the 91 cases, 14 (15%) did not fit
into the aforementioned predominant phenotypes. These
included 6 CRCCs, 1 ChC, 4 oncocytomas, and 3 PRCCs
(Table 2). Of these, the expression profiles of the 8
CK7–/KIT–/PAX2– neoplasms (6 CRCCs, 1 oncocytoma, and
1 PRCC) and 2 CK7–/KIT+/PAX2– oncocytomas are clearly
distinct from the usually CK7+ ChC. The 2
CK7+/KIT–/PAX2– PRCCs potentially overlap immunophe-
notypically with ChC but are generally easily distinguished
morphologically from them. This leaves 1 CK7+/KIT+/PAX2+
❚Table 3❚
Karyotypes of 11 Chromophobe Cell Carcinomas















❚Image 2❚ Representative karyotype of chromophobe renal
cell carcinoma (Table 3, case 5) showing multiple
chromosome losses, including chromosome 10, and t(3;8)
translocation.
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ChC and 1 CK7+/KIT+/PAX2+ oncocytoma as the 2 cases with
a truly confusing expression pattern with this panel. These cases
highlight the limitations of diagnostic immunohistochemical
analysis. The significance of immunostaining results should be
interpreted only in the context of morphologic evaluation. In
addition, the use of other markers such as RCC marker,
expressed by CRCC but not ChC or oncocytomas,15 or parval-
bumin, expressed by ChC but not CRCC or oncocytoma,21 may
be of value in the proper setting.
PAX2 is encoded on chromosome 10. Monosomy of
chromosome 10 is common in ChC.22 Cytogenetic data were
available for all 11 ChCs, of which 6 showed chromosome 10
losses. The 1 ChC case with PAX2 expression had no loss of
chromosome 10. The number of cases is too small for statisti-
cal analysis. However, these findings raise a question of a pos-
sible relationship between chromosome 10 loss and absence
of PAX2 expression. Evaluation of a larger number of ChCs is
needed to definitively address this question.
Our results demonstrate definite differences in CK7, KIT,
and PAX2 staining patterns of the major histologic subtypes of
renal neoplasms, indicating that this panel of immunostains
may be of value in the differential diagnosis of renal neo-
plasms. In addition, we demonstrated loss of PAX2 expression
in ChC and raised the question of whether this loss of PAX2
expression is related to loss of chromosome 10.
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